Silodosin Production Cost Reports

The report provides a detailed analysis essential for establishing a Silodosin manufacturing plant. It encompasses all critical aspects necessary for Silodosin production, including the cost of Silodosin production, Silodosin plant cost, Silodosin production costs, and the overall Silodosin manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Silodosin production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Silodosin (Rapaflo) is an FDA-approved drug that finds huge applications in the medical field. It is widely utilized as a medication for the treatment of dysuria related to benign prostatic hyperplasia. It also finds its application in treating the symptoms of benign prostatic hyperplasia in male adults. It is often employed as a medication for relaxing the lower urinary tract and relieving urinary symptoms in older men. Additionally, the compound is also used in alleviating bladder outlet obstruction, as it relaxes the smooth muscles of the urinary baldder neck.

The demand for Silodosin is largely led by its role as an α1-adrenoceptor antagonist with high uroselectivity, resulting in improved symptoms and urinary flow rates, which remarkably accelerates its market expansion. Its extensive usage as an oral drug for the treatment of dysuria associated with benign prostatic hypertrophy (BPH) in older males significantly boosts its demand in the medical and pharmaceutical industries.

Additionally, its employment in alleviating lower urinary tract symptoms that have a negative impact on the quality of life of patients further enhances its demand in the medical and healthcare industries. Furthermore, several factors influence industrial Silodosin procurement, including the availability of raw materials (N-acetyl-L-glutamic acid, etc.), cost and pricing, compliance with pharmaceutical regulations, quality standards, technological advancements, sustainability practices, distribution (including trading and shipping), logistics, safety standards, etc.

Raw Material for Silodosin Production

According to the Silodosin manufacturing plant project report, the major raw materials for Silodosin production include (R)-l-(3-Hydroxypropyl)-5-(2-(2- (2-(2, 2, 2-trifluoroethoxy) phenoxy) ethyl amino) propyl) Indoline-7-Carbonitrile- N-Acetyl-L-Glutamic Acid.

Manufacturing Process of Silodosin

The extensive Silodosin production cost report consists of the following industrial manufacturing process:

• Production via Chemical Synthesis: This method of production is initiated by the reaction of (R)-l-(3-hydroxypropyl)-5-(2-(2- (2-(2, 2, 2-trifluoroethoxy) phenoxy) ethyl amino) propyl) indoline-7-carbonitrile and N-acetyl-L-glutamic acid, followed by stirring at 25 °C for 5 hours and then at 5 to 10°C for 1 hour to produce N-acetyl-L-glutamate salt. Further, the obtained N-acetyl-L-glutamate salt is neutralized and hydrolyzed, which results in the formation of silodosin as the final product.

Silodosin is an indolecarboxamide that acts as an alpha-adrenergic Blocker. The molecular formula of the compound is C25H32F3N3O4, and its molecular weight is 495.5 g/mol. Moreover, the compound serves as a drug that is largely marketed under the trade names Rapaflo and Urorec. It is available in the form of oral capsules. Additionally, the melting point of the compound is >104°C and its boiling point is 601.4°C. It has a density of 1.249±0.06 g/cm3, and it is stored at -20°C in an inert atmosphere (under nitrogen or argon gas). The compound exists in the form of a white solid with a flash point of 317.5°C.